<DOC>
	<DOCNO>NCT01917279</DOCNO>
	<brief_summary>It phase III trial explore efficacy safety metronomic chemotherapy Capecitabine versus intermittent Capecitabine maintenance therapy follow first-line Capecitabine plus Docetaxel chemotherapy treatment HER2-negative metastatic breast cancer ( mBC ) .</brief_summary>
	<brief_title>Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel Treatment mBC</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Breast Diseases</mesh_term>
	<mesh_term>Neoplasms Site</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Signed informed consent obtain prior initiation studyspecific procedure treatment confirmation patient 's awareness willingness comply study requirement . Female patient age ≥ 18 year . Histologically confirm document HER2negative metastatic breast cancer . Previously untreated firstline chemotherapy . Patients least one measurable lesion accord RECIST criterion study entry . Documented ER/PgR status . Prior hormone therapy metastatic disease allow must stop study entry . KPS &gt; 70 . Life expectancy ≥12 week Previous chemotherapy metastatic breast cancer . Prior adjuvant/neoadjuvant chemotherapy within 6 month prior first study treatment administration . Prior ( radical ) radiotherapy treatment metastatic disease major surgical procedure within 28 day prior first study treatment , Inadequate bone marrow function : absolute neutrophil count ( ANC ) : &lt; 1.5 x 109/L , platelet count &lt; 75 x 109/L hemoglobin &lt; 100g/L . Inadequate liver renal function , define : 1 . Serum ( total ) bilirubin &gt; 2 x upper limit normal ( ULN ) institution 2 . AST/SGOT ALT/SGPT &gt; 2.5 x ULN ( &gt; 5 x ULN patient liver metastasis ) 3 . ALP &gt; 2.5 x ULN baseline ( &gt; 5 x ULN patient liver metastasis ) . 4 . Serum creatinine &gt; 140umol/L . Pregnant lactating female . Her2 positive ( ICH +++ FISH positive ) . Symptomatic cerebral parenchyma and/or leptomeningeal metastasis . Other malignancy within last 5 year , except adequately treat carcinoma situ cervix squamous carcinoma skin , adequately control limited basal cell skin cancer . Preexisting peripheral neuropathy ≥grade 1 accord NCI CTCAE 4.0 . Mental disease condition affect compliance patient . Other serious disease medical condition : 1 . History uncontrolled seizure , CNS disorder psychiatric disability judge Investigator clinically significant precluding inform consent . 2 . Congestive heart failure , unstable angina , myocardial infarction within ≤6 month prior first study treatment , uncontrolled hypertension high risk , uncontrolled arrhythmia . 3 . Uncontrolled acute infection Inability take absorption oral medication . Concurrent within 30 day use drug clinical trial . Previous treatment contain Capecitabine ( whether adjuvant palliative treatment ) . Previous treatment contain docetaxel within 12 month . Known hypersensitivity study treatment excipients . Any condition research consider appropriate take part trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Antimetabolites</keyword>
	<keyword>Tubulin Modulators</keyword>
	<keyword>Maintenance chemotherapy</keyword>
	<keyword>Metronomic chemotherapy</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Docetaxel</keyword>
</DOC>